查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602430

先進治療 CDMO 市場：按產品、階段、適應症和最終用戶 - 2025-2030 年全球預測

Advanced Therapy Medicinal Products CDMO Market by Products (Cell Therapy, Gene Therapy, Tissue Engineered), Phase (Phase I, Phase II, Phase III), Indication, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

先進治療CDMO市場2023年估值為75.4億美元，預計到2024年將達到87.4億美元，複合年成長率為17.06%，預計到2030年將達到227.4億美元。

先進治療藥物 (ATMP)受託製造廠商(CDMO) 在生物技術和製藥領域發揮著至關重要的作用，開發和開發基因療法、細胞療法和組織工程產品等創新治療方法，我們為製造提供基本服務。隨著對個人化醫療的需求不斷成長以及其他無法治癒疾病的治療方法的進步，對 ATMP 的需求更加突出，腫瘤學、罕見疾病、神經病學和再生醫學的應用範圍和最終用途正在擴大。該市場的關鍵成長要素包括細胞處理技術的進步、臨床試驗計劃數量的增加以及加快產品核可流程的有利法規結構。然而，在增強可擴展的製造流程和自動化技術方面仍然存在潛在的機會。利用這些機會可能需要投資來促進與專注於奈米級解決方案和生產分析數位基礎設施的生物技術公司的夥伴關係。然而，市場成長面臨著高昂的製造成本、嚴格的監管要求和缺乏熟練勞動力的挑戰，這可能會影響治療藥物的及時生產和供應。此外，供應鏈的複雜性和許多 ATMP 技術的早期階段等限制因素也構成了進一步的障礙。創新和研究的最佳途徑是改進反應器技術、改進基因編輯工具以及最佳化支援 ATMP 穩定性和分銷的低溫運輸物流。強調與學術機構和生物技術創新者的合作也可以促進技術突破。市場是動態的，具有源於治療方法進步和技術改進的高成長潛力，但必須克服監管和物流挑戰，以保持競爭力並最大化市場佔有率，您需要策略性地度過這一難關。

主要市場統計
基準年[2023] 75.4億美元
預測年份 [2024] 87.4億美元
預測年份 [2030] 227.4億美元
複合年成長率（%） 17.06%

市場動態：快速發展的先進治療 CDMO 市場的關鍵市場洞察

供需的動態交互作用正在改變先進療法 CDMO 市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 新感染疾病的出現導致罕見疾病迅速增加
    • 增加尖端治療藥物開發的臨床試驗數量
    • 全球醫藥研發投入增加
  • 市場限制因素
    • 與外包 ATMP 解決方案相關的高成本
  • 市場機會
    • 尖端治療 CDMO 採用尖端技術
    • 先進療法研究和開發的策略聯盟和擴展活動
  • 市場挑戰
    • 關於 ATMP核准和商業化的嚴格政府規章制度

波特五力：引領進治療 CDMO 市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解先進治療 CDMO 市場的外部影響

外部宏觀環境因素在塑造先進療法 CDMO 市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解先進治療藥物 CDMO 市場的競爭狀況

先進治療 CDMO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣先進療法 CDMO 市場供應商績效評估

FPNV定位矩陣是評估先進療法CDMO市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃先進療法 CDMO 市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，先進療法 CDMO 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 罕見疾病盛行率增加和新疾病出現

感染疾病

      • 增加先進治療藥物開發的臨床試驗
      • 全球藥品研發投資增加
    • 抑制因素
      • 與外包 ATMP 解決方案相關的高成本
    • 機會
      • 採用先進技術和先進療法

產品CDMO

      • 先進療法研究和開發的策略聯盟和擴展活動
    • 任務
      • ATMP核准和

商業化

  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章先進治療藥物 CDMO 市場：依產品

  • 細胞療法
  • 基因治療
  • 組織工程

第7章先進治療藥物 CDMO 市場分階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第8章先進治療藥物 CDMO 市場（按適應症）

  • 心臟病學
  • 中樞神經系統
  • 皮膚科
  • 內分泌、代謝、遺傳學
  • 胃腸病學
  • 血液學
  • 免疫學和發炎
  • 感染疾病
  • 肌肉骨骼
  • 腫瘤學
  • 眼科

第9章先進治療藥物 CDMO 市場：依最終用戶分類

  • 學術研究所
  • 生物技術和製藥公司
  • 臨床研究組織（CRO）
  • 醫院和診所

第10章：美洲先進治療CDMO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區先進治療藥物CDMO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章：歐洲、中東和非洲先進治療藥物CDMO市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abzena
  • Advanced Therapies, Inc. by WuXi AppTec
  • AGC Inc.
  • Aldevron
  • Almac Group
  • Arranta Bio Holdings, LLC
  • Bio Elpida
  • BlueReg
  • Catalent Inc.
  • CELONIC Group
  • CGT Catapult
  • Charles River Laboratories International, Inc.
  • Coriolis Pharma Research GmbH
  • Eurofins Scientific SE
  • FUJIFILM Corporation
  • Lonza Group
  • Minaris Regenerative Medicine
  • Oxford Biomedica PLC
  • Patheon by Thermo Fisher Scientific Inc.
  • Rentschler Biopharma SE
  • REPROCELL Inc.
  • RoslinCT
  • Samsung Biologics
  • VIVEBIOTECH SL
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market was valued at USD 7.54 billion in 2023, expected to reach USD 8.74 billion in 2024, and is projected to grow at a CAGR of 17.06%, to USD 22.74 billion by 2030.

Advanced Therapy Medicinal Products (ATMPs) Contract Development and Manufacturing Organizations (CDMOs) play a pivotal role in the biotechnology and pharmaceutical sectors, offering essential services in the development and production of innovative therapies such as gene therapies, cell therapies, and tissue-engineered products. The necessity for ATMPs is underscored by the rising demand for personalized medicine and the advancement of treatments for otherwise incurable diseases, which has exponentially driven the application and end-use scope within oncology, rare diseases, neurology, and regenerative medicine. Key growth influencers in this market include technological advancements in cell processing, an increasing number of clinical trial projects, and favorable regulatory frameworks that expedite product approval processes. However, potential opportunities remain within the enhancement of scalable manufacturing processes and automation technologies. To capitalize on these opportunities, investment in facilitating partnerships with biotech firms focusing on nanoscale solutions and digital infrastructure for production analytics could be vital. Nonetheless, market growth is challenged by high manufacturing costs, stringent regulatory requirements, and a shortage of skilled workforce which may impact timely production and delivery of therapies. Moreover, limitations such as supply chain complexities and the nascent stage of many ATMP technologies create further obstacles. The best avenues for innovation and research could be in enhancing bioreactor technologies, improving gene editing tools, and optimizing cold chain logistics to support the stability and distribution of ATMPs. Emphasizing collaborations with academic institutions and biotech innovators may also drive technological breakthroughs. The market is dynamic, with high growth potential rooted in both therapeutic advancements and technological augmentations, but necessitates strategic navigation through regulatory and logistical challenges to sustain competitive leverage and maximize market share.

KEY MARKET STATISTICS
Base Year [2023] USD 7.54 billion
Estimated Year [2024] USD 8.74 billion
Forecast Year [2030] USD 22.74 billion
CAGR (%) 17.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Advanced Therapy Medicinal Products CDMO Market

The Advanced Therapy Medicinal Products CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Proliferation in prevalence of rare diseases with growing emergence of novel infectious diseases
    • Rising numbers of clinical trials for development of advanced therapy medicinal products
    • Increasing investments in pharmaceutical research and development worldwide
  • Market Restraints
    • High cost associated with outsourcing ATMP solutions
  • Market Opportunities
    • Adoption of advanced technologies by advanced therapy medicinal products CDMOs
    • Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
  • Market Challenges
    • Stringent governmental rules and regulations for ATMP approvals and commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Advanced Therapy Medicinal Products CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Advanced Therapy Medicinal Products CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Advanced Therapy Medicinal Products CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Advanced Therapy Medicinal Products CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Advanced Therapy Medicinal Products CDMO Market

A detailed market share analysis in the Advanced Therapy Medicinal Products CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Advanced Therapy Medicinal Products CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Advanced Therapy Medicinal Products CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Advanced Therapy Medicinal Products CDMO Market

A strategic analysis of the Advanced Therapy Medicinal Products CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..

Market Segmentation & Coverage

This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Cell Therapy, Gene Therapy, and Tissue Engineered.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Indication, market is studied across Cardiology, Central Nervous System, Dermatology, Endocrine, Metabolic, Genetic, Gastroenterology, Hematology, Immunology & Inflammation, Infectious Disease, Musculoskeletal, Oncology, and Ophthalmology.
  • Based on End-Users, market is studied across Academic and Research Institutions, Biotechnology & Pharmaceutical Companies, Clinical Research Organizations (CROs), and Hospitals and Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Proliferation in prevalence of rare diseases with growing emergence of novel

infectious diseases

      • 5.1.1.2. Rising numbers of clinical trials for development of advanced therapy medicinal products
      • 5.1.1.3. Increasing investments in pharmaceutical research and development worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with outsourcing ATMP solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of advanced technologies by advanced therapy medicinal

products CDMOs

      • 5.1.3.2. Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and

commercialization

  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Advanced Therapy Medicinal Products CDMO Market, by Products

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Gene Therapy
  • 6.4. Tissue Engineered

7. Advanced Therapy Medicinal Products CDMO Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Advanced Therapy Medicinal Products CDMO Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Central Nervous System
  • 8.4. Dermatology
  • 8.5. Endocrine, Metabolic, Genetic
  • 8.6. Gastroenterology
  • 8.7. Hematology
  • 8.8. Immunology & Inflammation
  • 8.9. Infectious Disease
  • 8.10. Musculoskeletal
  • 8.11. Oncology
  • 8.12. Ophthalmology

9. Advanced Therapy Medicinal Products CDMO Market, by End-Users

  • 9.1. Introduction
  • 9.2. Academic and Research Institutions
  • 9.3. Biotechnology & Pharmaceutical Companies
  • 9.4. Clinical Research Organizations (CROs)
  • 9.5. Hospitals and Clinics

10. Americas Advanced Therapy Medicinal Products CDMO Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abzena
  • 2. Advanced Therapies, Inc. by WuXi AppTec
  • 3. AGC Inc.
  • 4. Aldevron
  • 5. Almac Group
  • 6. Arranta Bio Holdings, LLC
  • 7. Bio Elpida
  • 8. BlueReg
  • 9. Catalent Inc.
  • 10. CELONIC Group
  • 11. CGT Catapult
  • 12. Charles River Laboratories International, Inc.
  • 13. Coriolis Pharma Research GmbH
  • 14. Eurofins Scientific SE
  • 15. FUJIFILM Corporation
  • 16. Lonza Group
  • 17. Minaris Regenerative Medicine
  • 18. Oxford Biomedica PLC
  • 19. Patheon by Thermo Fisher Scientific Inc.
  • 20. Rentschler Biopharma SE
  • 21. REPROCELL Inc.
  • 22. RoslinCT
  • 23. Samsung Biologics
  • 24. VIVEBIOTECH S.L.

LIST OF FIGURES

  • FIGURE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ENDOCRINE, METABOLIC, GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 201. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023